全文获取类型
收费全文 | 1541篇 |
免费 | 93篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 124篇 |
妇产科学 | 29篇 |
基础医学 | 158篇 |
口腔科学 | 33篇 |
临床医学 | 169篇 |
内科学 | 277篇 |
皮肤病学 | 26篇 |
神经病学 | 150篇 |
特种医学 | 136篇 |
外科学 | 238篇 |
综合类 | 12篇 |
一般理论 | 1篇 |
预防医学 | 82篇 |
眼科学 | 17篇 |
药学 | 107篇 |
中国医学 | 2篇 |
肿瘤学 | 69篇 |
出版年
2023年 | 6篇 |
2022年 | 13篇 |
2021年 | 26篇 |
2020年 | 16篇 |
2019年 | 43篇 |
2018年 | 71篇 |
2017年 | 52篇 |
2016年 | 51篇 |
2015年 | 44篇 |
2014年 | 62篇 |
2013年 | 80篇 |
2012年 | 63篇 |
2011年 | 62篇 |
2010年 | 79篇 |
2009年 | 42篇 |
2008年 | 52篇 |
2007年 | 43篇 |
2006年 | 51篇 |
2005年 | 37篇 |
2004年 | 40篇 |
2003年 | 29篇 |
2002年 | 32篇 |
2001年 | 25篇 |
2000年 | 27篇 |
1999年 | 29篇 |
1998年 | 28篇 |
1997年 | 39篇 |
1996年 | 33篇 |
1995年 | 37篇 |
1994年 | 25篇 |
1993年 | 43篇 |
1992年 | 22篇 |
1991年 | 16篇 |
1990年 | 29篇 |
1989年 | 18篇 |
1988年 | 33篇 |
1987年 | 31篇 |
1986年 | 27篇 |
1985年 | 23篇 |
1984年 | 15篇 |
1983年 | 10篇 |
1982年 | 11篇 |
1981年 | 18篇 |
1980年 | 9篇 |
1979年 | 7篇 |
1978年 | 13篇 |
1977年 | 13篇 |
1976年 | 14篇 |
1975年 | 6篇 |
1972年 | 11篇 |
排序方式: 共有1636条查询结果,搜索用时 31 毫秒
1.
Giorgio Gandaglia Guillaume Ploussard Massimo Valerio Agostino Mattei Cristian Fiori Nicola Fossati Armando Stabile Jean-Baptiste Beauval Bernard Malavaud Mathieu Roumiguié Daniele Robesti Paolo Dell’Oglio Marco Moschini Stefania Zamboni Arnas Rakauskas Francesco De Cobelli Francesco Porpiglia Francesco Montorsi Alberto Briganti 《European urology》2019,75(3):506-514
Background
Available models for predicting lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) might not be applicable to men diagnosed via magnetic resonance imaging (MRI)-targeted biopsies.Objective
To assess the accuracy of available tools to predict LNI and to develop a novel model for men diagnosed via MRI-targeted biopsies.Design, setting, and participants
A total of 497 patients diagnosed via MRI-targeted biopsies and treated with RP and extended pelvic lymph node dissection (ePLND) at five institutions were retrospectively identified.Outcome measurements and statistical analyses
Three available models predicting LNI were evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analyses. A nomogram predicting LNI was developed and internally validated.Results and limitations
Overall, 62 patients (12.5%) had LNI. The median number of nodes removed was 15. The AUC for the Briganti 2012, Briganti 2017, and MSKCC nomograms was 82%, 82%, and 81%, respectively, and their calibration characteristics were suboptimal. A model including PSA, clinical stage and maximum diameter of the index lesion on multiparametric MRI (mpMRI), grade group on targeted biopsy, and the presence of clinically significant PCa on concomitant systematic biopsy had an AUC of 86% and represented the basis for a coefficient-based nomogram. This tool exhibited a higher AUC and higher net benefit compared to available models developed using standard biopsies. Using a cutoff of 7%, 244 ePLNDs (57%) would be spared and a lower number of LNIs would be missed compared to available nomograms (1.6% vs 4.6% vs 4.5% vs 4.2% for the new nomogram vs Briganti 2012 vs Briganti 2017 vs MSKCC).Conclusions
Available models predicting LNI are characterized by suboptimal accuracy and clinical net benefit for patients diagnosed via MRI-targeted biopsies. A novel nomogram including mpMRI and MRI-targeted biopsy data should be used to identify candidates for ePLND in this setting.Patient summary
We developed the first nomogram to predict lymph node invasion (LNI) in prostate cancer patients diagnosed via magnetic resonance imaging-targeted biopsy undergoing radical prostatectomy. Adoption of this model to identify candidates for extended pelvic lymph node dissection could avoid up to 60% of these procedures at the cost of missing only 1.6% patients with LNI. 相似文献2.
D Gröne† R Treudler† EM de Villiers‡ R Husak† CE Orfanos† ChC Zouboulis†§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(2):202-205
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment. 相似文献
3.
Six patients who injured their wrists had radiographs documenting a dorsal, 5- to 10-mm oblong fragment of bone immediately proximal to the base of the fourth and/or fifth metacarpal bones. The fragment was seen on the pronation oblique and/or lateral projections, but not on the posteroanterior projection. The radiographic appearance of the fragment was remarkably similar in all cases. In the one patient in which it was performed, pluridirectional tomography demonstrated that the fragment originated from the dorsal surface of the hamate. Five of the six patients also had associated posterior dislocation of the fourth and/or fifth metacarpals. We conclude that this fragment represents a coronal fracture through the body of the hamate resulting from posterior dislocation or subluxation of the fourth and/or fifth metacarpal. 相似文献
4.
5.
6.
目的评价β-受体阻滞剂治疗老年冠心病慢性心力衰竭的疗效及安全性。方法105例老年冠心病慢性心力衰竭患者按就诊顺序随机分为两组,美托洛尔组52例在常规抗心力衰竭治疗基础上加用美托洛尔12.5~25mg,2/d;对照组53例采用常规抗心力衰竭治疗,未用美托洛尔。定期来诊随访,观察临床表现,监测治疗前后心率、血压、心功能参数变化。结果美托洛尔组显效率53.8%,总有效率88.5%;对照组显效率30.2%,总有效率67.9%,两者比较有显著性差异(P〈0.05)。美托洛尔组患者心率减慢、血压降低较对照组明显,超声心动图复查显示治疗6个月后左室舒张末期内径缩小,左室射血分数增高较对照组显著。结论美托洛尔为老年冠心病慢性心力衰竭提供一种较为安全有效的药物治疗手段。 相似文献
7.
8.
9.
The receptor tyrosine kinase (RTK) Ret is activated by the formation of a complex consisting of ligands such as glial cell line-derived neurotrophic factor (GDNF) and glycerophosphatidylinositol-anchored coreceptors termed GFRalphas. During activation, Ret translocates into lipid rafts, which is critical for functional responses to GDNF. We found that Ret was rapidly ubiquitinated and degraded in sympathetic neurons when activated with GDNF, but, unlike other RTKs that are trafficked to lysosomes for degradation, Ret was degraded predominantly by the proteasome. After GDNF stimulation, the majority of ubiquitinated Ret was located outside of lipid rafts and Ret was lost predominantly from nonraft membrane domains. Consistent with the predominance of Ret degradation outside of rafts, disruption of lipid rafts in neurons did not alter either the GDNF-dependent ubiquitination or degradation of Ret. GDNF-mediated survival of sympathetic neurons was inhibited by lipid raft depletion, and this inhibitory effect of raft disruption on GDNF-mediated survival was reversed if Ret degradation was blocked via proteasome inhibition. Therefore, lipid rafts sequester Ret away from the degradation machinery located in nonraft membrane domains, such as Cbl family E3 ligases, thereby sustaining Ret signaling. 相似文献
10.
Plasma level Studies on Volunteers after Intramuscular Application of Different Doses of Etofenamate in Oily Solution. After i.m. injections of etofenamate (active substance of Rheumon i.m.) in oily solution to 12 volunteers, courses of plasma levels of etofenamate, flufenamic acid and fenamate (sum of etofenamate and flufenamic acid) were measured by HPTLC. Maximum levels of etofenamate, flufenamic acid and fenamate, as well as areas under the plasma level time curve (AUC) after 250, 500 and 1000 mg etofenamate respectively are proportional to dose. Maxima of fenamate plasma levels are reached after 6.3, 6.2 and 5.4 h respectively, half maximal levels are present already after 2 h. The mean residence time is 21.8, 18.8 and 15.7 h. These values obtained from different doses are not statistically different from each other. Pharmacokinetics are therefore linear and dose independent. The courses of fenamate levels can be described by a two compartment model. The elimination half lives after 250, 500 and 1000 mg are 2.1, 2.3 and 1.9 h, the invasion half-lives (dominant half-life) 8.8, 7.8 and 6.8 h. Terminal half-lives are 50.3, 63.7 and 35.4 h. Since plasma levels have decreased to 2% of the maximum level after one terminal half-life, they have no practical importance for the duration of activity or for accumulation. No sex related differences are found for dose dependent and independent parameters. From the data it can be derived that after i.m. injection of etofenamate in oily solution a prolongation of the dominant half-life occurs by a factor of 4-5 (as compared to oral data) which is caused by prolonged liberation from the oily depot. This long lasting liberation of etofenamate leads to a prolonged residence time after a fast increase, at the same time avoiding unnecessary high peak levels. Therefore it is guaranteed that even after i.m. administration of 1000 mg etofenamate in oily solution plasma levels of fenamate do not exceed those after 300 mg given orally. According to pharmacokinetic data a fast onset of action, good tolerability and a therapeutic action over a period of 24 h can be expected. 相似文献